Huawei's AI Scandal Just Exploded--And Investors Should Be Paying Attention
This isn't just a code reviewit's a window into the internal pressure mounting inside China's AI champions. With Alibaba and DeepSeek making waves and catching investor attention, Huawei's rare public statement signals how high the stakes are becoming. The companylong a symbol of China's tech self-sufficiencynow finds itself on the defensive in one of the hottest battlegrounds: sovereign AI. The fact that Huawei had to respond at all speaks volumes. IP compliance, innovation speed, and trust are no longer soft issuesthey're table stakes in an environment where reputations are earned (or lost) in public.
For global investors watching the AI value chainfrom chipmakers like Nvidia (NASDAQ:NVDA) to downstream platforms like Tesla (NASDAQ:TSLA)this is another flashing signal. The game isn't just about who builds the fastest model. It's also about who's playing fair, who's shipping on time, and who's earning credibility in a world that increasingly demands transparency. As China's AI ecosystem matures, these reputational battles could become just as important as the hardware wars.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet
Canopy Growth seems unable to overcome the industrywide challenges it faces. Novavax's recent quarterly update, though strong, says little about its prospects. 10 stocks we like better than Canopy Growth › Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so. You should be careful to avoid catching falling knives. Let's consider two stocks that have significantly lagged the market in recent years but could still fall further: Canopy Growth (NASDAQ: CGC) and Novavax (NASDAQ: NVAX). Canopy Growth emerged as a leader in the cannabis industry toward the end of the past decade. The company has significant operations in Canada, the U.S., and various countries worldwide, including Germany. Despite its position in these markets, Canopy Growth has been a profoundly disappointing investment over the past five years. Its latest results provided another example as to why. During the fourth quarter of its fiscal 2025, which ended March 31, Canopy Growth's net revenue declined by 11% year over year to 65 million Canadian dollars ($47.6 million). The company's loss per share for the period was CA$1.43 ($1.05), worse than the CA$1.03 ($0.75) it reported in the prior-year quarter. In fairness, Canopy Growth's troubles aren't entirely its fault. The cannabis industry has been a mess due to legal and regulatory challenges; competition from illicit channels, sometimes even where the product is legal; and oversupply, particularly in Canada, which legalized recreational use of cannabis for adults in 2018. Hardly any pot company has found consistent success over the past five years, despite different focuses, strategies, and executions across the industry. That may suggest the problem is not exclusive to specific companies. No matter whose fault it is, though, Canopy Growth's business is in shambles, and things are not about to get better. True, the company is engaged in cost-cutting efforts while refocusing its portfolio in Canada on in-demand items, such as vapes and pre-rolls. Management predicts that it will achieve positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in "the near-term." Yet, even if Canopy Growth gets there, positive EBITDA would only be a step toward profitability. The company's efforts to reduce expenses may help boost margins in the short term. But it's challenging to envision a path for it to perform well in the long run, given the industry challenges that have led to inconsistent financial results over the past half-decade. Are investors to believe that, after all this time and countless failures across the industry -- both those of Canopy Growth and of others -- the company has finally cracked the code? Convincing the market that that's the case will require more than just positive adjusted EBITDA. I see little reason to expect the pot grower to perform well over the next five years. In fact, I'd expect the stock to sink even further -- and advise investors to stay far away. Examining Novavax's financial results and recent progress may suggest that the stock is a compelling investment opportunity. In the first quarter, the company's revenue was $666.7 million, compared to just $93.9 million for the comparable period of the previous fiscal year. Net income was $518.6 million, compared to a net loss of $147.6 million in the first quarter of 2024. Furthermore, Novavax recently reported positive results from phase 3 studies for its stand-alone influenza vaccine and combination COVID-19/flu vaccine. That's to say nothing of the partnerships it's signed with companies like Sanofi and Takeda Pharmaceuticals, which have paid Novavax for the rights to its COVID vaccines in various countries. But can the company sustain its performance over the long run? Probably not, and here's why. First, the coronavirus vaccine market has been inconsistent and hard to predict. Recent regulatory guidance in the U.S. may further complicate matters, with the Department of Health and Human Services no longer recommending the vaccine for certain populations, including pregnant women and healthy children. It's also worth noting that Novavax has generally played second fiddle to the leaders in this space, Moderna and Pfizer. Novavax's strong financial results in the first quarter are not at all indicative of how it will perform year in and year out. Second, the company's phase 3 wins for its two leading vaccines were not significant achievements. Although they induced strong immune responses in participants, Novavax itself states that these trials were not designed to demonstrate statistical significance. In other words, these results won't support approval. And while they're a good stepping stone to phase 3 studies that would, Novavax is waiting for a partner with big pockets to run these trials. That means it either doesn't have the funds to go at it alone, or management doesn't think doing so without a partner will be worth the investment -- or both. Even if it does find a partner, other companies (including Moderna) have made significant strides in developing competing vaccines. Lastly, the infusion of cash it received from its partnership with Sanofi will eventually run out. The company's business will likely have little to show for itself after that point. All these factors make Novavax unattractive to long-term investors, as the stock could fall much further than it has in the past five years. Before you buy stock in Canopy Growth, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Canopy Growth wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $694,758!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $998,376!* Now, it's worth noting Stock Advisor's total average return is 1,058% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. 2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet was originally published by The Motley Fool
Yahoo
26 minutes ago
- Yahoo
5 No-Brainer Artificial Intelligence (AI) Stocks to Buy on the Dip
The stocks on this list have performed well since the AI boom started in 2023. Their underlying businesses are poised to grow for years to come. Investors should view share price declines as opportunities to buy and hold for the next five years or longer. 10 stocks we like better than Palantir Technologies › It's probably safe to say that artificial intelligence (AI) is here to stay. Investments in AI infrastructure continue to soar, and companies are racing to develop and implement AI in nearly every facet of their business models. Researchers believe that over time, artificial intelligence will impact many of the world's jobs and create trillions of dollars in economic growth. Some of the top AI stocks have already generated impressive returns for investors since the AI market rally began in 2023. However, given the long-term growth likely ahead, it would be wise to view price declines as opportunities to buy into companies leading the AI wave. Here are five no-brainer AI winners that investors should buy on the dip and hold for the next five years and beyond. AI is ultimately software, and Palantir Technologies (NASDAQ: PLTR) is among the best at helping its government and corporate customers wield AI's potential. Palantir develops custom AI software on its proprietary platforms, which can perform a range of tasks, from identifying fraud to optimizing supply chains to supporting military missions. Palantir's revenue growth has continued to accelerate since last summer, following the launch of its Artificial Intelligence Platform (AIP). Almost any company large enough to invest in AI software is a potential Palantir client. There are over 20,000 large companies in the United States alone, and Palantir still has just 622 commercial customers. The stock's valuation is extremely rich at the moment, making it an obvious candidate to revisit when the price drops. On the hardware side of AI are semiconductors (chips), also known as the building blocks of technology. Arm Holdings (NASDAQ: ARM) designs proprietary processing chip architectures and generates revenue from licensing fees and royalties. Arm's customers include the leading AI chip companies, such as Nvidia. To date, customers have shipped over 310 billion Arm-based chips, and Arm continues to increase its market share. Arm is highly profitable, as it has almost zero expenses outside of research and development. Global chip demand is increasing over time as AI, cloud computing, autonomous vehicles, and other emerging technologies require more processing power. Analysts estimate that Arm will grow earnings by an average of 22% annually over the long term, an impressive pace. However, its steep forward price-to-earnings (P/E) ratio of 85 means investors should probably wait to buy for now. Electronics giant Apple (NASDAQ: AAPL) has a massive AI opportunity in front of it. The company's iOS ecosystem boasts over 2.3 billion active users across smartphones, computers, and wearable devices. Unfortunately, Apple has gotten off to a slow start with AI, reportedly going back to the drawing board to fix its Siri voice assistant product. Despite the struggles, Apple likely has time to figure things out thanks to its famously sticky ecosystem. In the meantime, Apple is still poised to enjoy double-digit annualized earnings growth, partly due to its massive stock buyback programs, which steadily reduce the share count and increase earnings per share. There's a reason it's one of Warren Buffett's favorite stocks. Apple stock still has long-term upside, but it would be best to buy once its valuation falls from its current P/E ratio of 30 times 2025 earnings estimates. Social media juggernaut Meta Platforms (NASDAQ: META) is leveraging AI in many ways. It developed and open-sourced its Llama AI model, accumulating over 1.2 billion downloads. It is also building a consumer ecosystem with Meta-branded headsets and smart glasses, an effort to break free from the control that smartphone makers have had over its apps. AI is also helping to enhance Meta's core business, which is advertising to the 3.4 billion people using its apps each day. Meta has integrated AI into its ads business to increase monetization. Eventually, AI could automate ads, likely boosting profit margins for a company that was exceptionally lucrative to begin with. The stock's P/E ratio (28) has drifted higher since 2023, but anticipated mid-teens annualized earnings growth makes Meta a table-pounding buy on pullbacks. Semiconductor giant Broadcom (NASDAQ: AVGO) is experiencing increased growth due to surging demand for its AI networking chips, as well as its custom accelerator chips (XPUs). The company's AI-related semiconductor revenue grew by 46% year over year in the second quarter of 2025 and could add billions of dollars in incremental revenue over the coming years. Investors may also like that Broadcom isn't a pure AI investment. Infrastructure software for enterprises has become a significant portion of Broadcom's business, accounting for approximately 40% of its revenue. Additionally, the stock offers a rising dividend that management has increased for 15 consecutive years. Analysts anticipate 25% annualized earnings growth over the next three to five years, making Broadcom a solid buy at 41 times 2025 earnings estimates and a no-brainer if the stock drops further. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,432!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,854!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Meta Platforms, Nvidia, and Palantir Technologies. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. 5 No-Brainer Artificial Intelligence (AI) Stocks to Buy on the Dip was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
With 89% ownership of the shares, Analog Devices, Inc. (NASDAQ:ADI) is heavily dominated by institutional owners
Significantly high institutional ownership implies Analog Devices' stock price is sensitive to their trading actions The top 23 shareholders own 50% of the company Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If you want to know who really controls Analog Devices, Inc. (NASDAQ:ADI), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are institutions with 89% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. In the chart below, we zoom in on the different ownership groups of Analog Devices. View our latest analysis for Analog Devices Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. As you can see, institutional investors have a fair amount of stake in Analog Devices. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Analog Devices' historic earnings and revenue below, but keep in mind there's always more to the story. Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Hedge funds don't have many shares in Analog Devices. The Vanguard Group, Inc. is currently the largest shareholder, with 10.0% of shares outstanding. With 7.9% and 4.6% of the shares outstanding respectively, BlackRock, Inc. and State Street Global Advisors, Inc. are the second and third largest shareholders. Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 23 shareholders, meaning that no single shareholder has a majority interest in the ownership. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our information suggests that Analog Devices, Inc. insiders own under 1% of the company. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. Though their holding amounts to less than 1%, we can see that board members collectively own US$310m worth of shares (at current prices). In this sort of situation, it can be more interesting to see if those insiders have been buying or selling. The general public-- including retail investors -- own 10% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Analog Devices has 1 warning sign we think you should be aware of. But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
